Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 13, pp. 1196-1206
Open Access | Times Cited: 625

Showing 1-25 of 625 citing articles:

The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 306
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
Yuting Lu, Xiangliang Yuan, Miao Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 279
Antibodies to watch in 2023
Hélène Kaplon, Silvia Crescioli, Alicia M. Chenoweth, et al.
mAbs (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 212
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Estelle Baulu, Célia Gardet, Nicolas Chuvin, et al.
Science Advances (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 207
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (2022) Vol. 170, pp. 256-284
Open Access | Times Cited: 193
Managing Metastatic Melanoma in 2022: A Clinical Review
Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, et al.
JCO Oncology Practice (2022) Vol. 18, Iss. 5, pp. 335-351
Open Access | Times Cited: 147
Advances in the clinical management of uveal melanoma
Richard D. Carvajal, Joseph J. Sacco, Martine J. Jager, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 99-115
Closed Access | Times Cited: 136
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
T-cell-engaging bispecific antibodies in cancer
Niels W.C.J. van de Donk, Sonja Zweegman
The Lancet (2023) Vol. 402, Iss. 10396, pp. 142-158
Closed Access | Times Cited: 123
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 120
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 117
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Kailin Yang, Ahmed Halima, Timothy A. Chan
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 604-623
Closed Access | Times Cited: 115
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Jing Wei, Yueyao Yang, Gang Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Lisa H. Butterfield, Yana G. Najjar
Nature reviews. Immunology (2023) Vol. 24, Iss. 6, pp. 399-416
Closed Access | Times Cited: 100
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2364-2373
Open Access | Times Cited: 95
ALK-positive lung cancer: a moving target
Jaime L. Schneider, W. Marston Linehan, Alice T. Shaw
Nature Cancer (2023) Vol. 4, Iss. 3, pp. 330-343
Closed Access | Times Cited: 93
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2256-2266
Open Access | Times Cited: 93
Metastatic uveal melanoma: The final frontier
Elina Rantala, Micaela Hernberg, Sophie Piperno‐Neumann, et al.
Progress in Retinal and Eye Research (2022) Vol. 90, pp. 101041-101041
Closed Access | Times Cited: 92
Systemic Therapy for Melanoma: ASCO Guideline Update
Rahul Seth, Sanjiv S. Agarwala, Hans Messersmith, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 30, pp. 4794-4820
Open Access | Times Cited: 90
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 78
Tebentafusp: First Approval
Sohita Dhillon
Drugs (2022) Vol. 82, Iss. 6, pp. 703-710
Open Access | Times Cited: 70
New immune cell engagers for cancer immunotherapy
Aurore Fenis, Olivier Demaria, Laurent Gauthier, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 7, pp. 471-486
Closed Access | Times Cited: 67
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
Margret Merino, Yvette L. Kasamon, Marc R. Theoret, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2706-2712
Open Access | Times Cited: 66
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Christopher A. Klebanoff, Smita S. Chandran, Brian M. Baker, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 996-1017
Open Access | Times Cited: 65
The landscape of T cell antigens for cancer immunotherapy
Aviyah Peri, Nadja Salomon, Yochai Wolf, et al.
Nature Cancer (2023) Vol. 4, Iss. 7, pp. 937-954
Closed Access | Times Cited: 62
Page 1 - Next Page

Scroll to top